Better Therapeutics Inc. and Glooko, Inc. announced a partnership to integrate Better Therapeutics? AspyreRx? digital behavioral treatment for type 2 diabetes (T2D) into Glooko?s diabetes management platform.

This collaboration will enable healthcare providers in the United States who use the Glooko platform to identify suitable patients for AspyreRx, facilitate prescriptions, and track patients throughout their treatment. In the United States alone, Glooko?s solutions have aided over 3.4 million people with diabetes and are utilized in nearly 5,000 clinic locations. AspyreRx will be accessible on the Glooko healthcare provider (HCP) platform in the U.S. as a new treatment option.

Additionally, by leveraging Glooko?s 'precision engagement' functionality, patients who are suitable candidates for AspyreRx will be flagged for healthcare providers.